If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Retatrutide-Diabetes
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling.
What retatrutide clinical trials are being conducted in people with type 2 diabetes?
The TRANSCEND-T2D clinical trial program evaluates investigational doses of retatrutide for the treatment of type 2 diabetes in adults.
TRANSCEND-T2D Clinical Trial Program: Retatrutide for the Treatment of Type 2 Diabetes
Retatrutide is a novel, synthetic molecule, which shows potent agonist action at the
- glucose-dependent insulinotropic polypeptide receptor (GIPR),
- glucagon-like peptide-1 receptor (GLP-1R), and
- glucagon receptor (GCGR).1
The TRANSCEND-T2D clinical trial program assesses the efficacy and safety of investigational doses of retatrutide as a treatment for type 2 diabetes in adults (Overview of the TRANSCEND-T2D Phase 3 Clinical Trial Program of Retatrutide for the Treatment of T2D).
Trial and Target Population |
Key Inclusion Criteria |
Concomitant Therapya |
Retatrutide Groups |
Comparator |
Primary Endpoint(s) |
Primary Timepoint |
Global trials |
||||||
TRANSCEND-T2D-12 |
|
None |
Administered SC |
PBOb |
CFB in HbA1c (%) |
40 weeks |
TRANSCEND-T2D-23 |
|
Metformin with or without |
Administered SC |
SEMAb |
CFB in HbA1c (%) |
80 weeks |
TRANSCEND-T2D-34 |
|
Basal insulin with or without metformin and/or SGLT2i |
Administered SC |
PBOb |
CFB in HbA1c (%) |
52 weeks |
Abbreviations: BMI = body mass index; CFB = change from baseline; HbA1c = glycated hemoglobin; PBO = placebo; SC = subcutaneously; SEMA = semaglutide; SGLT2i = sodium-glucose cotransporter-2 inhibitor; T2D = type 2 diabetes.
aFor the treatment of T2D.
bAdministered SC.
References
1Coskun T, Rosenstock J, Frías JP, et al. Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36-week, phase 2 study. Oral presentation at: 59th Annual Meeting of the European Association for the Study of Diabetes (EASD); October 2-6, 2023; Hamburg, Germany. Accessed March 12, 2024. https://www.easd.org/media-centre/home.html#!resources/retatrutide-a-triple-gip-glp-1-glucagon-receptor-agonist-provides-robust-hba-sub-1c-sub-and-body-weight-reductions-to-people-with-type-2-diabetes-a-36-week-phase-2-study
2Effect of retatrutide compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone (TRANSCEND-T2D-1). ClinicalTrials.gov identifier: NCT06354660. Updated April 19, 2024. Accessed April 22, 2024. https://clinicaltrials.gov/study/NCT06354660
3Effect of retatrutide compared with semaglutide in adult participants with type 2 diabetes and inadequate glycemic control with metformin with or without SGLT2 inhibitor (TRANSCEND-T2D-2). ClinicalTrials.gov identifier: NCT06260722. Updated April 17, 2024. Accessed April 23, 2024. https://clinicaltrials.gov/study/NCT06260722
4Effect of retatrutide compared with placebo in participants with type 2 diabetes and moderate or severe renal impairment, with inadequate glycemic control on basal insulin, with or without metformin and/or SGLT2 inhibitor (TRANSCEND-T2D-3). ClinicalTrials.gov identifier: NCT06297603. Updated April 11, 2024. Accessed April 23, 2024. https://clinicaltrials.gov/study/NCT06297603
Date of Last Review: March 12, 2024